$25.54
+3.20 (+14.32%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where BDSX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
4 observational
Held by 6 tracked-famous managers (MARSHALL WACE, LLP, JANE STREET GROUP, LLC, TWO SIGMA INVESTMENTS, LP, RENAISSANCE TECHNOLOGIES LLC, Squarepoint Ops LLC, +1 more) · FINRA short interest 2.7 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|
| A Multicenter, Retrospective, Chart Review Study Evaluating the Impact and Utility of the Blood-Based Proteomic Integrated Classifier and Auto-Antibody Tests in the Real-WorldNCT06728319observationalAssess Test Performance of AAT test | — | Active, not recruiting | Lung Nodules | 4,000 | 2026-07-31 | 2025-02-07 |
| Clinical Effectiveness Assessment of VeriStrat® Testing and Validation of Immunotherapy Tests in NSCLC SubjectsNCT03289780observationalPhysician Treatment Patterns DescriptionStudy Protocol ↗ · Informed Consent Form ↗ | — | Active, not recruiting | Non-Small Cell Lung Cancer | 5,006 | Dec 2025 | 2025-09-19 |
| Nodify XL2 Classifier Clinical Utility Study in Low to Moderate Risk Lung NodulesNCT04171492observationalLung Nodule Diagnosis | — | Active, not recruiting | Nodule Solitary Pulmonary, Non-small Cell Carcinoma | 2,000 | Dec 2025 | 2025-09-19 |
| A Registry to Evaluate the Performance of the BDX-XL2 TestNCT03766958observationalStatistically significant change in the proportion of benign lung nodules managed by Nodify Lung experiencing invasive procedures. | — | Completed | Nodule Solitary Pulmonary, NSCLC | 842 | 2022-05-12actual | 2024-05-24 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19